Response to preoperative chemoradiation in Stage II and III rectal cancer

Craig L. Brown, Charles A. Ternent, Alan G. Thorson, Mark A. Christensen, Garnet J. Blatchford, Maniamparampil Shashidharan, Gleb Haynatzki

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

PURPOSE: The purpose of this study was to determine whether a complete pathologic response after neoadjuvant therapy in rectal cancer patients improves disease control and survival. METHODS: The study reviewed Stage II and III rectal cancer patients treated with preoperative chemoradiation and resected for cure. Complete pathologic response was defined as no cancer in the resected specimen. The main outcome measures were cancer-specific and disease-free survival in patients achieving a complete pathologic response and a noncomplete pathologic response. Kaplan-Meier curves were evaluated using log-rank analysis. RESULTS: Eighty-nine rectal cancer patients received neoadjuvant chemoradiation followed by radical resection for cure. Twenty-one patients (24 percent) achieved a complete pathologic response. Median follow-up for the complete pathologic response group was 23.5 months and 31 months for the noncomplete pathologic response group. There were more Stage III patients in the noncomplete pathologic response group than the complete pathologic response group (P = 0.005). Complete pathologic response patients were less likely to receive postoperative adjuvant chemotherapy than noncomplete pathologic response patients (P = 0.004). Cancer-specific and disease-free survival were not statistically different between the two groups. However, a trend was noted toward improved survival and decreased recurrence in association with a complete pathologic response. CONCLUSION: Stage III patients were less likely to be in the complete pathologic response group than Stage II patients. Complete pathologic response patients were less likely to receive postoperative adjuvant chemotherapy than noncomplete pathologic response patients. Complete pathologic response after neoadjuvant chemoradiation for rectal cancer patients demonstrated a trend toward improved survival and decreased recurrence compared with noncomplete pathologic response patients.

Original languageEnglish (US)
Pages (from-to)1189-1193
Number of pages5
JournalDiseases of the Colon and Rectum
Volume46
Issue number9
DOIs
StatePublished - Sep 1 2003

Fingerprint

Rectal Neoplasms
Adjuvant Chemotherapy
Disease-Free Survival
Survival
Recurrence
Neoplasms
Neoadjuvant Therapy

Keywords

  • Biological response
  • Chemoradiation
  • Neoadjuvant
  • Rectal cancer
  • Survival

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Brown, C. L., Ternent, C. A., Thorson, A. G., Christensen, M. A., Blatchford, G. J., Shashidharan, M., & Haynatzki, G. (2003). Response to preoperative chemoradiation in Stage II and III rectal cancer. Diseases of the Colon and Rectum, 46(9), 1189-1193. https://doi.org/10.1007/s10350-004-6714-y

Response to preoperative chemoradiation in Stage II and III rectal cancer. / Brown, Craig L.; Ternent, Charles A.; Thorson, Alan G.; Christensen, Mark A.; Blatchford, Garnet J.; Shashidharan, Maniamparampil; Haynatzki, Gleb.

In: Diseases of the Colon and Rectum, Vol. 46, No. 9, 01.09.2003, p. 1189-1193.

Research output: Contribution to journalArticle

Brown, CL, Ternent, CA, Thorson, AG, Christensen, MA, Blatchford, GJ, Shashidharan, M & Haynatzki, G 2003, 'Response to preoperative chemoradiation in Stage II and III rectal cancer', Diseases of the Colon and Rectum, vol. 46, no. 9, pp. 1189-1193. https://doi.org/10.1007/s10350-004-6714-y
Brown CL, Ternent CA, Thorson AG, Christensen MA, Blatchford GJ, Shashidharan M et al. Response to preoperative chemoradiation in Stage II and III rectal cancer. Diseases of the Colon and Rectum. 2003 Sep 1;46(9):1189-1193. https://doi.org/10.1007/s10350-004-6714-y
Brown, Craig L. ; Ternent, Charles A. ; Thorson, Alan G. ; Christensen, Mark A. ; Blatchford, Garnet J. ; Shashidharan, Maniamparampil ; Haynatzki, Gleb. / Response to preoperative chemoradiation in Stage II and III rectal cancer. In: Diseases of the Colon and Rectum. 2003 ; Vol. 46, No. 9. pp. 1189-1193.
@article{870d793215c34e8a8640c23cc997aa40,
title = "Response to preoperative chemoradiation in Stage II and III rectal cancer",
abstract = "PURPOSE: The purpose of this study was to determine whether a complete pathologic response after neoadjuvant therapy in rectal cancer patients improves disease control and survival. METHODS: The study reviewed Stage II and III rectal cancer patients treated with preoperative chemoradiation and resected for cure. Complete pathologic response was defined as no cancer in the resected specimen. The main outcome measures were cancer-specific and disease-free survival in patients achieving a complete pathologic response and a noncomplete pathologic response. Kaplan-Meier curves were evaluated using log-rank analysis. RESULTS: Eighty-nine rectal cancer patients received neoadjuvant chemoradiation followed by radical resection for cure. Twenty-one patients (24 percent) achieved a complete pathologic response. Median follow-up for the complete pathologic response group was 23.5 months and 31 months for the noncomplete pathologic response group. There were more Stage III patients in the noncomplete pathologic response group than the complete pathologic response group (P = 0.005). Complete pathologic response patients were less likely to receive postoperative adjuvant chemotherapy than noncomplete pathologic response patients (P = 0.004). Cancer-specific and disease-free survival were not statistically different between the two groups. However, a trend was noted toward improved survival and decreased recurrence in association with a complete pathologic response. CONCLUSION: Stage III patients were less likely to be in the complete pathologic response group than Stage II patients. Complete pathologic response patients were less likely to receive postoperative adjuvant chemotherapy than noncomplete pathologic response patients. Complete pathologic response after neoadjuvant chemoradiation for rectal cancer patients demonstrated a trend toward improved survival and decreased recurrence compared with noncomplete pathologic response patients.",
keywords = "Biological response, Chemoradiation, Neoadjuvant, Rectal cancer, Survival",
author = "Brown, {Craig L.} and Ternent, {Charles A.} and Thorson, {Alan G.} and Christensen, {Mark A.} and Blatchford, {Garnet J.} and Maniamparampil Shashidharan and Gleb Haynatzki",
year = "2003",
month = "9",
day = "1",
doi = "10.1007/s10350-004-6714-y",
language = "English (US)",
volume = "46",
pages = "1189--1193",
journal = "Diseases of the Colon and Rectum",
issn = "0012-3706",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Response to preoperative chemoradiation in Stage II and III rectal cancer

AU - Brown, Craig L.

AU - Ternent, Charles A.

AU - Thorson, Alan G.

AU - Christensen, Mark A.

AU - Blatchford, Garnet J.

AU - Shashidharan, Maniamparampil

AU - Haynatzki, Gleb

PY - 2003/9/1

Y1 - 2003/9/1

N2 - PURPOSE: The purpose of this study was to determine whether a complete pathologic response after neoadjuvant therapy in rectal cancer patients improves disease control and survival. METHODS: The study reviewed Stage II and III rectal cancer patients treated with preoperative chemoradiation and resected for cure. Complete pathologic response was defined as no cancer in the resected specimen. The main outcome measures were cancer-specific and disease-free survival in patients achieving a complete pathologic response and a noncomplete pathologic response. Kaplan-Meier curves were evaluated using log-rank analysis. RESULTS: Eighty-nine rectal cancer patients received neoadjuvant chemoradiation followed by radical resection for cure. Twenty-one patients (24 percent) achieved a complete pathologic response. Median follow-up for the complete pathologic response group was 23.5 months and 31 months for the noncomplete pathologic response group. There were more Stage III patients in the noncomplete pathologic response group than the complete pathologic response group (P = 0.005). Complete pathologic response patients were less likely to receive postoperative adjuvant chemotherapy than noncomplete pathologic response patients (P = 0.004). Cancer-specific and disease-free survival were not statistically different between the two groups. However, a trend was noted toward improved survival and decreased recurrence in association with a complete pathologic response. CONCLUSION: Stage III patients were less likely to be in the complete pathologic response group than Stage II patients. Complete pathologic response patients were less likely to receive postoperative adjuvant chemotherapy than noncomplete pathologic response patients. Complete pathologic response after neoadjuvant chemoradiation for rectal cancer patients demonstrated a trend toward improved survival and decreased recurrence compared with noncomplete pathologic response patients.

AB - PURPOSE: The purpose of this study was to determine whether a complete pathologic response after neoadjuvant therapy in rectal cancer patients improves disease control and survival. METHODS: The study reviewed Stage II and III rectal cancer patients treated with preoperative chemoradiation and resected for cure. Complete pathologic response was defined as no cancer in the resected specimen. The main outcome measures were cancer-specific and disease-free survival in patients achieving a complete pathologic response and a noncomplete pathologic response. Kaplan-Meier curves were evaluated using log-rank analysis. RESULTS: Eighty-nine rectal cancer patients received neoadjuvant chemoradiation followed by radical resection for cure. Twenty-one patients (24 percent) achieved a complete pathologic response. Median follow-up for the complete pathologic response group was 23.5 months and 31 months for the noncomplete pathologic response group. There were more Stage III patients in the noncomplete pathologic response group than the complete pathologic response group (P = 0.005). Complete pathologic response patients were less likely to receive postoperative adjuvant chemotherapy than noncomplete pathologic response patients (P = 0.004). Cancer-specific and disease-free survival were not statistically different between the two groups. However, a trend was noted toward improved survival and decreased recurrence in association with a complete pathologic response. CONCLUSION: Stage III patients were less likely to be in the complete pathologic response group than Stage II patients. Complete pathologic response patients were less likely to receive postoperative adjuvant chemotherapy than noncomplete pathologic response patients. Complete pathologic response after neoadjuvant chemoradiation for rectal cancer patients demonstrated a trend toward improved survival and decreased recurrence compared with noncomplete pathologic response patients.

KW - Biological response

KW - Chemoradiation

KW - Neoadjuvant

KW - Rectal cancer

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0141675100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141675100&partnerID=8YFLogxK

U2 - 10.1007/s10350-004-6714-y

DO - 10.1007/s10350-004-6714-y

M3 - Article

VL - 46

SP - 1189

EP - 1193

JO - Diseases of the Colon and Rectum

JF - Diseases of the Colon and Rectum

SN - 0012-3706

IS - 9

ER -